Clinical Potential of Omega-3 Fatty Acids in the Treatment of Schizophrenia

CNS Drugs

Volumn 17, Issue 15, 2003, Pages 1081-1091

  Emsley, Robin ^a   Oosthuizen, Piet ^a   Van Rensburg, Susan J ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID ETHYL ESTER; NEUROLEPTIC AGENT; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; CELL MEMBRANE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; ERYTHROCYTE MEMBRANE; ESSENTIAL FATTY ACID DEFICIENCY; FLUSHING; HUMAN; MALE; MONOTHERAPY; NEGATIVE SYNDROME; NERVE CELL MEMBRANE; POSITIVE SYNDROME; PRIORITY JOURNAL; RATING SCALE; RETINA; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SKIN FIBROBLAST; TREATMENT OUTCOME;

ADULT; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA;

EID: 0345802805     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317150-00003     Document Type: Review

References (56)

1. Emsley R. Partial response to antipsychotic treatment: the patient with enduring symptoms. J Clin Psychiatry 1999; 60 Suppl. 23: 10-3
2. Thomas CS, Lewis S. Which atypical antipsychotic? Br J Psychiatry 1998; 172: 106-9
3. Marder SR. Management of treatment-resistant patients with schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 11: 26-30
4. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995; 10 (4): 207-13
5. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55 (3): 250-8
6. Meltzer HY. Suicide and schizophrenia: clozapine and the InterSePT study: International Clozaril/Leponex Suicide Prevention Trial. J Clin Psychiatry 1999; 60 Suppl. 12: 47-50
7. Rossi A, Mancini F, Stratta P, et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 1997; 95 (1): 40-3
8. Franz M, Lis S, Pluddemann K, et al. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997; 170: 422-5
9. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23-30
10. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 11: 53-60
11. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96
12. Clark C, Burge MR. Diabetes mellitus associated with atypical anti-psychotic medications. Diabetes Technol Ther 2003; 5 (4): 669-83
13. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003 Jul 8 [Epub ahead of print]
14. Emsley RA, Oosthuizen PP, Joubert AJ, et al. Treatment of schizophrenia in low-income countries. Int J Neuropsychopharmacol 1999; 2: 321-5
15. Horrobin DF, Glen AI, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 1994; 13 (3): 195-207
16. Horrobin DF, Manku MS. Clinical biochemistry of essential fatty acids. In: Horrobin DF, editor. Omega-6 essential fatty acids. New York: Wiley Liss, 1990: 21-53
17. Horrobin D, Bennett CN. Phospholipid spectrum disorders in psychiatry and neurology. 2nd ed. Carnforth, UK: Marius Press, 2003
18. Horrobin DF. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977; I (8018): 936-7
19. Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Acids 1996; 55 (1-2): 3-7
20. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophrenia Res 2001; 30: 193-208
21. Nasrallah HA. Neurodevelopmental pathogenesis of schizophrenia. Psychiatr Clin North Am 1993; 16: 269-80
22. Sinclair HM. Deficiency of essential fatty acids and atherosclerosis et cetera. Lancet 1956; I: 381-3
23. McNeil TF, Cantor-Graae E, Nordstrom LG. et al. Head circumference in 'preschizophrenic' and control neonates. Br J Psychiatry 1993; 162: 517-23
24. McNeil TF, Kaij L. Obstetric factors in the development of schizophrenia: complications in the births of preschizophrenics and in reproduction by schizophrenic patients. In: Wynne LC, Cromwell RL, Matthysee S, editors. The nature of schizophrenia. New York: John Wiley and Sons, 1978: 401-29
25. Selten JP, van Durursen R, van der Graaf C, et al. Second-trimester exposure to maternal stress is a possible factor for psychotic illness in the child [abstract]. Schizophr Res 1997; 24: 258
26. Edwards RH, Peet M. Essential fatty acid intake in relation to depression. In: Peet M. Glen I, Horrobin DF, editors. Phospholipid spectrum disorder in psychiatry. Carnforth, UK: Marius Press, 1999
27. Kirsten GF, Smuts CM, Tichelaar HY, et al. The effect of severe pre-eclampsia on maternal and cord erythrocyte membrane essential fatty acid profiles. S Afr Med J 1998, 629
28. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 463-93
29. Edwards R, Peet M, Shay J, et al. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affective Disord 1998; 48: 149-55
30. Vaddadi KS. Essential fatty acids and movement disorders. In: Peet M, Glen I, Horrobin D, editors. Phospholipid spectrum disorder in psychiatry. Carnforth, UK: Marius Press, 1999
31. Puri B, Bydder GM, Counsell SJ, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002; 13: 123-6
32. Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatr Scand 1988; 78 (5): 587-91
33. Peet M, Laugharne J, Rangarajan N, et al. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 1995; 29 (3): 227-32
34. Vaddadi KS, Gilleard CJ, Soosai E, et al. Schizophrenia, tardive dyskinesia and essential fatty acids. Schizophr Res 1996; 20 (3): 287-94
35. Mahadik SP, Mukherjee S, Horrobin DF, et al. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res 1996; 63 (2-3): 133-42
36. Assies J, Lieverse R, Vreken P, et al. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry 2001; 49: 510-22
37. Yao J, Stanley JA, Reddy RD, et al. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biol Psychiatry 2002; 52: 823-30
38. Glen AIM, Cooper SJ, Rybakowski J, et al. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 9-15
39. Ward PE, Sutherland J, Glen EM, et al. Niacin skin flush in schizophrenia: a preliminary report. Schizophr Res 1998; 29: 269-74
40. Mahadik SP, Shendarkar NS, Scheffer RE, et al. Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 65-70
41. Warner R. Laugharne J, Peet M. et al. Retinal function as a marker for cell membrane omega-3 fatty acid depletion in schizophrenia: a pilot study. Biol Psychiatry 1999; 45: 1138-42
42. Skinner FK, MacDonell LEF, Glen I. Retinal function in schizophrenia. In: Peet M, Glen I, Horrobin DF. editors. Phospholipid spectrum disorder in psychiatry. Carnforth, UK: Marius Press, 1999: 121-31
43. Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 2000; 42: 7-17
44. Richardson AJ, Easton T, Gruzelier JH, et al. Laterality changes accompanying symptom remission in schizophrenia following treatment with eicosapentaenoic acid. Int J Psychophysiol 1999; 34 (3): 333-9
45. Su KP, Shen WW, Huang SY. Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. Eur Neuropsychopharmacol 2001; 11 (4): 295-9
46. Laugharne JD, Mellor JE, Peet M. Fatty acids and schizophrenia. Lipids 1996; 31 Suppl.: S163-5
47. Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001; 49 (3): 243-51
48. Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 158 (12): 2071-4
49. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7-18
50. Emsley R, Myburgh C, Oosthuizen P, et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159 (9): 1596-8
51. Horrobin DF, Jenkins K, Bennett CN, et al. Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 83-90
52. Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. Eur Psychiatry 2001; 16: 418-23
53. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000; 47: 8-21
54. Maidment ID. Are fish oils an effective therapy in mental illness: an analysis of the data. Acta Psychiatr Scand 2000; 102 (1): 3-11
55. Freeman MP. Omega-3 fatty acids in psychiatry: a review. Ann Clin Psychiatry 2000; 12: 159-65
56. Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid (fish or evening primrose oil) for schizophrenia. Cochrane Database Systematic Reviews. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Oxford Update Software, 2000: CD001257